Teicoplanin
Antimicrobial / ClinicalAlso known as: Targocid
Mechanism
A glycopeptide antibiotic widely used in Europe (though not approved in the US) as an alternative to vancomycin. Better tolerated than vancomycin (less "Red Man syndrome"), can be given IM (not just IV), and only needs once-daily dosing. Particularly useful for bone and joint infections due to excellent tissue penetration. A complex of 5 related compounds.
Technical detail
Lipoglycopeptide complex of 5 closely related compounds (TA2-1 through TA2-5, differing in fatty acid acyl chain length C10-C11), plus a related compound RS-1, produced by Actinoplanes teichomyceticus. Mechanism: identical to vancomycin — binds D-Ala-D-Ala terminus of peptidoglycan precursors via 5 hydrogen bonds, blocking transglycosylation. However, lipophilic acyl chain provides membrane anchoring, increasing drug concentration at site of action. Better tissue penetration (bone, lung) than vancomycin. Pharmacokinetics: long half-life (100-170 hours), high protein binding (90-95%), allows once-daily dosing (6-12 mg/kg IV/IM after loading). Can be given IM (vancomycin cannot). TDM target: trough >15-30 µg/mL. Lower nephrotoxicity and histamine release than vancomycin.
Effects
ANTIMICROBIAL MECHANISM: Natural glycopeptide antibiotic produced by Actinoplanes teichomyceticus. Binds D-Ala-D-Ala terminus of peptidoglycan precursors (lipid II), blocking both transglycosylation and transpeptidation — same fundamental mechanism as vancomycin. However, teicoplanin has a lipophilic acyl side chain (C10-C11 fatty acid) that anchors in the cell membrane, providing enhanced potency and a longer half-life compared to vancomycin. This membrane-anchoring also provides some membrane-disrupting activity (intermediate between vancomycin and lipoglycopeptides). SPECTRUM: Gram-positive organisms: MRSA (MIC90 1-2 μg/mL), MSSA, CoNS, streptococci (including S. pneumoniae), E. faecalis (MIC90 0.5-1 μg/mL), C. difficile. IMPORTANT: Teicoplanin has REDUCED activity against E. faecium compared to vancomycin — MIC often 4-16 μg/mL. Some MRSA strains show heterogeneous teicoplanin resistance. No Gram-negative activity. MIC BREAKPOINTS: EUCAST: S. aureus susceptible ≤2 μg/mL; Enterococcus susceptible ≤2 μg/mL; Streptococcus susceptible ≤2 μg/mL. CLSI: does not provide teicoplanin breakpoints (not marketed in US). RESISTANCE: VanA-type VRE — resistant (same as vancomycin). VanB-type — RETAINS activity (unlike vancomycin which is resistant). This VanB susceptibility is a significant clinical advantage in regions with VanB-dominant VRE. PHARMACOKINETICS: Long half-life ~70-100 hours (much longer than vancomycin's 6-12 hours) — enables once-daily dosing after loading. High protein binding (90-95%). Vd ~0.7-1.4 L/kg. Good tissue penetration into bone, lung, and soft tissue. Renal elimination — dose adjust for CrCl <30 mL/min. Can be given IM (unlike vancomycin) — useful in outpatient settings. TOXICITY: Better tolerated than vancomycin in multiple comparative studies. Less nephrotoxicity than vancomycin (no mandatory TDM, though recommended for efficacy). No red-man syndrome (minimal histamine release). Less ototoxicity. Adverse effects: rash (3%), fever, transient liver enzyme elevation, thrombocytopenia (rare but monitor). Anaphylaxis very rare.
Practitioner Guide
CLINICAL PEARLS — INFECTIOUS DISEASE SPECIALIST PERSPECTIVE: DOSING: LOADING IS CRITICAL. Standard: 12 mg/kg IV/IM q12h x 3 doses (days 1-2), then 12 mg/kg IV/IM once daily. For severe/deep-seated infections (endocarditis, bone): loading 12 mg/kg q12h x 3-5 doses, then 12 mg/kg once daily. Target trough: >15 μg/mL for skin/soft tissue; >20 μg/mL (some say >30) for bone/joint and endocarditis. UNDERDOSING IS THE #1 PROBLEM: Historical loading regimens (6 mg/kg) produced subtherapeutic levels. The 12 mg/kg loading regimen is now standard. Many clinical failures attributed to teicoplanin were likely due to inadequate dosing. THE EUROPEAN VANCOMYCIN: Teicoplanin is widely used in Europe, UK, Asia, and Australia as an alternative to vancomycin. Not marketed in the US (never sought FDA approval). Its tolerability profile is notably better than vancomycin. IM ADMINISTRATION: Unique among glycopeptides — teicoplanin can be given intramuscularly. This enables outpatient treatment without IV access. IM bioavailability is ~90%. Inject deep IM (gluteal). Useful for OPAT programs in settings without easy IV access. WHEN TO CHOOSE TEICOPLANIN: (1) Vancomycin intolerance (nephrotoxicity, red-man syndrome, allergy). (2) Outpatient treatment when IM route is preferred. (3) VanB VRE infections (teicoplanin retains activity). (4) Once-daily dosing convenience. (5) Patients with renal impairment (less nephrotoxic, though still renally cleared). LIMITATIONS: Not as potent as daptomycin or lipoglycopeptides against MRSA. Some MRSA strains with vancomycin MIC creep also show teicoplanin MIC creep. E. faecium activity is unreliable. Not available in US. MONITORING: Trough levels recommended (not mandatory like vancomycin). Draw pre-dose after steady state (~day 4). Target >15-20 μg/mL for most infections, >20-30 for deep-seated. Renal function baseline and weekly. CBC weekly (thrombocytopenia surveillance). Liver function baseline and periodic. COMBINATION THERAPY: Combine with rifampin for prosthetic joint infections (same principle as vancomycin + rifampin). Combine with gentamicin for enterococcal endocarditis. Can combine with fosfomycin for synergy against MRSA. STORAGE: Reconstituted solution stable at room temperature for 24 hours. IM injections may be painful — consider lidocaine dilution.
Research Summary
TIER 1 (Gold Standard): Multiple RCTs comparing teicoplanin to vancomycin for Gram-positive infections — meta-analysis (Cavalcanti et al., 2010) showed similar efficacy with significantly fewer adverse effects (nephrotoxicity, red-man syndrome) for teicoplanin. Wood et al., 1996 — RCT teicoplanin vs. vancomycin for serious Gram-positive infections. Licensed in Europe (1988), UK, Japan, Australia, and many other countries. Not FDA-approved (never applied). TIER 2 (Strong): Pea et al., 2003 — PK and dosing optimization (Clinical Pharmacokinetics, PMID: 12603173). Byrne et al., 2017 — systematic review of teicoplanin loading doses. EUCAST breakpoints and susceptibility data. BSAC/BNF guidelines recommending teicoplanin. DrugBank DB06149. TIER 3 (Moderate): Extensive European clinical experience spanning 35+ years. UK OPAT programs widely use teicoplanin for IM outpatient therapy. Clinical observations on underdosing as cause of treatment failure (historical learning). International data: particularly strong experience in UK, Italy (where it was developed), Japan, and Australia. Conference presentations at ECCMID, BSAC. WHO Essential Medicines List inclusion. KEY FINDINGS: (1) Comparable efficacy to vancomycin with better tolerability profile. (2) IM administration capability is a unique practical advantage. (3) Loading dose is critical — underdosing caused historical failures. (4) VanB VRE activity gives it a niche role. (5) Once-daily dosing simplifies administration. GAPS: Modern RCTs comparing to newer agents (daptomycin, lipoglycopeptides). Optimal trough targets for deep-seated infections. Activity against emerging MRSA clones with reduced glycopeptide susceptibility. Why it was never brought to the US market. ACTIVE TRIALS: Limited new trials — well-established agent. Ongoing surveillance studies.